African swine fever virus pnp868r protein monoclonal antibody and application thereof
By preparing and purifying a monoclonal antibody against the ASFV pNP868R protein, the problem of ASFV detection was solved, enabling specific identification and early diagnosis of ASFV, and providing technical support for the prevention and control of ASF.
Patent Information
- Application Number
- CN202511572433.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-10-30
- Publication Date
- 2026-06-23
AI Technical Summary
There is a lack of effective ASFV antibody detection methods in the current technology, making it difficult to achieve early diagnosis and prevention of ASF. In addition, the clinical symptoms of ASF are similar to those of other swine diseases, resulting in a high rate of misdiagnosis.
A monoclonal antibody with high affinity and specificity for ASFV pNP868R protein was developed. It was prepared and purified by hybridoma technology and used for Western blotting and indirect immunofluorescence experiments to capture proteins that interact with pNP868R protein.
It enables the specific identification and detection of ASFV, provides a theoretical basis for the pathogenesis of ASFV, and supports the early diagnosis and prevention of ASF.
Smart Images

Figure CN122255260A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biotechnology, specifically relating to a monoclonal antibody against the pNP868R protein of African swine fever virus and its application. Background Technology
[0002] African swine fever (ASF) is an acute infectious disease caused by the African swine fever virus (ASFV) infecting domestic and wild pigs. This disease is highly destructive, clinically characterized by high fever, bleeding from the skin and internal organs, ataxia, and loss of appetite. The mortality rate in infected pigs can reach 100%, posing a significant threat and economic loss to the pig farming industry. The World Organisation for Animal Health (OIE) lists ASF as a legally notifiable animal disease, and my country classifies it as a Class A animal infectious disease. It is primarily transmitted through direct and indirect contact. Direct contact transmission occurs mainly between infected and healthy pigs, with the virus entering the healthy pig's body through the skin and mucous membranes. Indirect contact includes transmission through contaminated feed, air, and water. Additionally, ASFV can be transmitted via vectors such as ticks. Currently, the prevention and control of this disease is a crucial and urgent issue facing my country and the world. The clinical symptoms of ASF are very similar to those of other swine diseases with high fever and hemorrhagic disease, such as classical swine fever and swine reproductive and respiratory syndrome, making it difficult to differentiate and diagnose clinically. Therefore, laboratory diagnosis is crucial for the prevention and control of this disease.
[0003] African swine fever virus (ASFV) belongs to the family Asfarviridae and the genus Asfivirus, and is the only member of this family. The ASFV genome is 170–194 kb in size; it is a large nucleoplasmic DNA virus with 150–167 open reading frames encoding 150–200 proteins. The virus particle is approximately 260 nm in diameter and exhibits icosahedral symmetry. B646L The 3' end sequence of the gene can classify ASFV strains into 24 major genotypes. Currently, ASF in my country presents a complex situation of mixed prevalence, including high-lethality genotype II strains, medium / low-lethality genotype II deletion strains, low-lethality genotype I strains, and high-lethality genotype I / II recombinant strains. Since there are no safe and effective vaccines or treatments, research into other antiviral strategies will provide technical means for the prevention and control of this disease.
[0004] NP868RThe gene is located in the central stable region of the ASFV genome, and its encoded protein, pNP868R, is a core component of the viral capsid, crucial for capsid assembly and stability. Secondly, the pNP868R protein participates in the formation of the ASFV capping complex, playing a key role in the transcriptional regulation of the viral genome. Furthermore, pNP868R is also involved in the host's innate immune response and escape. Currently, ASF detection primarily relies on polymerase chain reaction (PCR), which detects the ASFV genome, while detection methods for ASFV antibodies are relatively lacking. Summary of the Invention
[0005] To address the aforementioned technical problems, this invention provides a monoclonal antibody with good affinity for the ASFV pNP868R protein and its uses. The monoclonal antibody is characterized by high titer, strong affinity, and good specificity, and can specifically bind to the pNP868R protein. Specifically, it includes the following: In a first aspect, the present invention provides a monoclonal antibody against the African swine fever virus pNP868R protein, the monoclonal antibody comprising a heavy chain variable region and a light chain variable region; the heavy chain variable region comprising CDR1 shown in SEQ ID NO.3, CDR2 shown in SEQ ID NO.5, and CDR3 shown in SEQ ID NO.7; the light chain variable region comprising CDR1 shown in SEQ ID NO.10, CDR2 shown in SEQ ID NO.12, and CDR3 shown in SEQ ID NO.14.
[0006] Preferably, the heavy chain variable region further includes FR1 shown in SEQ ID NO.2, FR2 shown in SEQ ID NO.4, FR3 shown in SEQ ID NO.6, and FR4 shown in SEQ ID NO.8; the light chain variable region further includes FR1 shown in SEQ ID NO.9, FR2 shown in SEQ ID NO.11, FR3 shown in SEQ ID NO.13, and FR4 shown in SEQ ID NO.15.
[0007] Preferably, both the heavy and light chains of the monoclonal antibody are of the IgG1 type.
[0008] Secondly, the present invention provides a nucleic acid that encodes the monoclonal antibody described in the first aspect above.
[0009] Thirdly, the present invention provides the application of the monoclonal antibody described in the first aspect above in the preparation of reagents, test strips, or kits for detecting African swine fever virus.
[0010] Fourthly, the present invention provides a kit for detecting African swine fever virus, the kit comprising the monoclonal antibody described in the first aspect above.
[0011] Fifthly, the present invention provides the application of the monoclonal antibody described in the first aspect or the kit described in the fourth aspect in the in vitro detection of African swine fever virus for non-disease diagnosis purposes.
[0012] In a sixth aspect, the present invention provides the use of the monoclonal antibody described in the first aspect above in capturing proteins that interact with pNP868R.
[0013] In a seventh aspect, the present invention provides a method for preparing the monoclonal antibody described in the first aspect above, the method comprising: inoculating BALB / c mice with recombinant African swine fever virus pNP868R protein as an antigen, fusing spleen cells from immunized mice with SP2 / 0 myeloma cells, obtaining hybridoma cells after subclonal screening and indirect ELISA identification, and the hybridoma cells producing the monoclonal antibody.
[0014] Preferably, the amino acid sequence of the African swine fever virus pNP868R recombinant protein is shown in SEQ ID NO. 1.
[0015] Preferably, the monoclonal antibody is obtained by injecting the hybridoma cells into BALB / c mice, collecting ascites fluid 3-6 days after injection, centrifuging, mixing the supernatant with an equal volume of PBS buffer, adjusting the pH to 7.4, and then loading the mixture onto a Protein A / G chromatography column at a slow flow rate, collecting the flowthrough. After loading, the mixture is eluted three times, followed by antibody elution.
[0016] The beneficial effects of this invention are: First, this invention uses pNP868R protein prepared by eukaryotic expression as an antigen to immunize BALB / c mice. Using hybridoma technology, through cell fusion, indirect ELISA screening, limiting dilution subcloning, and continuous hybridoma passage culture, a hybridoma cell line 6C14E11 that can stably secrete monoclonal antibodies against African swine fever virus pNP868R protein was obtained. The hybridoma cells can be stably passaged and continuously secrete anti-pNP868R monoclonal antibodies. Secondly, the present invention obtained a monoclonal antibody against African swine fever virus pNP868R protein secreted by the hybridoma cell line 6C1 4E11. The monoclonal antibody can specifically recognize African swine fever virus pNP868R protein and can be used for Western blotting and indirect immunofluorescence experiments. Moreover, the monoclonal antibody can be used to capture proteins that interact with the pNP868R protein, providing a theoretical basis for further elucidating the pathogenic mechanism of ASFV. Attached Figure Description
[0017] To more clearly illustrate the technical solutions of the embodiments of this disclosure, the accompanying drawings used in the embodiments will be briefly introduced below. The following drawings only show some embodiments of this disclosure and should not be regarded as a limitation on the scope. For those skilled in the art, other related drawings can be obtained from these drawings without creative effort.
[0018] Figure 1 SDS-PAGE image validating the expression of recombinant protein pNP868R of African swine fever virus.
[0019] Figure 2 Molecular sieve purification peak chromatogram and SDS-PAGE image used to validate the purification of recombinant pNP868R protein of African swine fever virus.
[0020] Figure 3 SDS-PAGE image for purification and validation of anti-pNP868R monoclonal antibody (M: protein marker; 1: purified 6C1 4E11 monoclonal antibody).
[0021] Figure 4 To detect the titer of monoclonal antibodies using an indirect ELISA method.
[0022] Figure 5 Western-Blot analysis of pNP868R protein expressed at different time points after ASFV infection by anti-pNP868R monoclonal antibody 6C14E11 (A) and pNP868R protein expressed 24 h after ASFV infection by different concentrations of anti-pNP868R monoclonal antibody 6C14E11 (B).
[0023] Figure 6 Indirect immunofluorescence assay was used to identify the anti-pNP868R protein monoclonal antibody 6C1 4E11.
[0024] Figure 7 To identify subtypes using the Proteintech subtype identification kit via an indirect ELISA method.
[0025] Figure 8 An immunoprecipitation experiment was performed using anti-pNP868R monoclonal antibody and Protein A / G agarose, with mouse IgG as a negative antibody control. The immunoprecipitated samples were then subjected to Western blot analysis.
[0026] Figure 9 To conduct an immunoprecipitation experiment with anti-pNP868R monoclonal antibody and Protein A / G agarose, mouse IgG was used as a negative antibody control, and the immunoprecipitated samples were then subjected to silver staining detection again. Detailed Implementation
[0027] The following detailed description of embodiments of the present invention is intended to further illustrate the claims of this disclosure, but should not be construed as limiting the invention. Any limited modifications made within the scope of the claims of this disclosure are still within the scope of protection of the claims of this disclosure. Unless otherwise specified, specific conditions in the embodiments are performed under conventional conditions or conditions recommended by the manufacturer. Unless otherwise stated, all reagents used in the following embodiments are commercially available or can be synthesized according to methods described herein or known to the art. Reaction conditions not listed are readily available to those skilled in the art.
[0028] Unless otherwise defined herein, the scientific and technical terms used in connection with this disclosure shall have the meanings commonly understood by one of ordinary skill in the art. Exemplary methods and materials are described below, but similar or equivalent methods and materials to those described herein may also be used in the practice or testing of this disclosure.
[0029] Experimental materials: Porcine alveolar macrophages (PAMs) were prepared and cryopreserved in our laboratory; The genotype II ASFV CN / GS / 2018 strain was provided by the National African Swine Fever Regional Laboratory of Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences. Human embryonic kidney cells (HEK 293F) and SP2 / 0 mouse myeloma cells were preserved in our laboratory; pCDNA3.4(+) vector was purchased from Wuhan Miaoling Biotechnology Co., Ltd.; SPF-grade BALB / C mice were purchased from Hubei Provincial Experimental Animal Research Center.
[0030] Example 1: Expression of recombinant pNP868R protein of African swine fever virus The amino acid sequence of the pNP868R recombinant protein is as follows: MASLDNLVARYQRCFNDQSLKNSTIELEIRFQQINFLLFKTVYEALVAQEIPSTISHSIRCIKKVHHENHCREKILPSENLYFKKQPLMFFKFSEPASLGCKVSLAIEQPIRKFILDSSILVRLKNRTTFRVSELWKIELTIVKQLMGSEVSAKLAAFKTLLFDTPEQQTTKNMMTLINPDDEYLYEIEIEYTGKPESLTAADVIKIKNTVLTLISPNHLMLTAYHQAIEFIASHILSSEILLARIKSGKWGLKRLLPQVKSMTKADYMKFYPPVGYYVTDKADGIRGIAVIQDTQIYVVADQLYSLGTTGIEPLKPTILDGEFMPEKKEFYGFDVIMYEGNLLTQQGFETRIESLSKGIKVLQAFNIKAEMKPFISLTSADPNVLLKNFESIFKKKTRPYSIDGIILVEPGNSYLNTNTFKWKPTWDNTLDFLVRKCPESLNVPEYAPKKGFSLHLLFVGISGELFKKLALNWCPGYTKLFPVTQRNQNYFPVQFQPSDFPLAFLYYHPDTSSFSNIDGKVLEMRCLKREINHVSWEIVKIREDRQQDLKTGGYFGNDFKTAELTWLNYMDPFSFEELAKGPSGMYFAGAKTGIYRAQTALISFIKQEIIQKISHQSWVIDLGIGKGQDLGRYLDAGIRHLVGIDKDQTALAELVYRKFSHATTRQHKHATNIYVLHQDLAEPAKEISEKVHQIYGFPKEGASSIVSNLFIHYLMKNTQQVENLAVLCHKLLQPGGMVWFTTMLGEQVLELLHENRIELNEVWEARENEVVKFAIKRLFKEDILQETGQEIGVLLPFSNGDFYNEYLVNTAFLIKIFKHHGFSLVQKQSFKDWIPEFQNFSKSLYKILTEADKTWTSLFGFICLRKN (shown in SEQ ID NO.1).
[0031] Construct the African swine fever virus pNP868R recombinant plasmid; control the density of HEK 293F cells at 2×10 6Around 24 hours later, the correctly sequenced African swine fever virus pNP868R recombinant plasmid was transfected into HEK 293F cells and cultured at 37°C in a 5% CO2 shaker for 24 h. After 24 h, to increase expression levels, enhancers (3.4 ml valproic acid, 1.3 ml sodium propionate, 4 ml glucose) were added, and the cells were cultured again at 37°C in a 5% CO2 shaker. After 72 h, the cells were collected, lysed, and centrifuged. The supernatant and precipitate were collected separately. The supernatant was incubated with Strep-Tactin® XT 4 Flow® high-capacity reagent at 4°C for 6 h, and then washed with protein buffer (40 mM Tris-HCl, 200 mM NaCl, 5 mM DTT, pH=8.0). Proteins bound to magnetic beads were eluted with 50 mM biotin. 80 μL of each protein sample was added to 20 μL of 5× loading buffer and incubated in a 100℃ water bath for 15 min. SDS-PAGE gel electrophoresis and Coomassie brilliant blue staining were then performed to identify whether pNP868R was expressed and the solubility of the expressed protein.
[0032] The results are as follows Figure 1 As shown, the full-length pNP868R protein can express a band of approximately 99 kDa.
[0033] Example 2: Purification of recombinant pNP868R protein of African swine fever virus
[0034] The pNP868R recombinant protein obtained in Example 1 was purified using a molecular sieve and affinity chromatography. The peak chromatogram of the African swine fever virus pNP868R recombinant protein after molecular sieve purification and SDS-PAGE identification of the purified recombinant protein are shown below. Figure 2 As shown.
[0035] The results showed that the size of the target band matched the expected protein size, indicating that the full-length pNP868R protein had been successfully purified.
[0036] Example 3: Determination of serum titer in mice immunized with recombinant African swine fever virus pNP868R protein
[0037] The purified and concentrated recombinant pNP868R protein was mixed with Freund's complete adjuvant and then emulsified. Six 8-week-old BALB / c mice were given their first subcutaneous immunization. Subsequently, the prepared recombinant protein was mixed with Freund's incomplete adjuvant for second, third, and fourth immunizations, with each immunization interval being 14 days. Blood was collected from the tail vein of mice after the third and fourth immunizations, and serum was analyzed using an indirect ELISA method to determine antibody titers. The serum titers of pNP868R recombinant protein-immunized mice are shown in Tables 1 and 2.
[0038]
[0039] Note: The reading is OD. 450nm value.
[0040]
[0041] Note: The reading is OD. 450nm value.
[0042] As shown in Tables 1 and 2, after immunization with the pNP868R recombinant protein, all 6 mice had high serum antibody titers, meeting the fusion requirements. Among them, the serum titer of mouse No. 2 was the highest.
[0043] Example 4: Preparation of anti-pNP868R monoclonal antibody
[0044] The results of the above-mentioned mouse serum titer detection were analyzed. Spleen cells from mouse No. 2 were fused with mouse myeloma cells SP2 / 0 and subjected to three subclonal screenings. Using an indirect ELISA method, a hybridoma cell line capable of stably secreting pNP868R monoclonal antibody was successfully screened. 1×10⁻⁶ cells were then used. 6 6C1 4E11 hybridoma cells were injected intraperitoneally into BALB / c mice. Ten days later, ascites fluid was collected, and the antibody-containing ascites fluid was pretreated and purified using Protein A / G agarose. The purified antibody 6C1 4E11 was analyzed for purity by SDS-PAGE, with a concentration of 9 mg / mL, and aliquoted and stored at -80°C. Protein A / G agarose purification of mouse ascites fluid removed other contents, and the purified antibody 6C1 4E11 contained only heavy and light chain structures. Results are as follows... Figure 3 The results showed bands at approximately 55 kDa and 25 kDa, consistent with the expected protein size, representing the heavy and light chains, respectively. These results indicate that the antibody 6C1 4E11 was successfully purified.
[0045] Example 5: Titer determination of anti-pNP868R monoclonal antibody
[0046] The purified pNP868R recombinant protein was coated onto an ELISA plate at a concentration of 1 µg / mL. The monoclonal antibody 6C1 4E11 obtained in Example 4 was used as the primary antibody, and mouse negative serum was used as a control. The antibody titer was detected by indirect ELISA.
[0047] The results are as follows Figure 4 As shown, the purified monoclonal antibody 6C1 4E11 has a titer of 1:9216000, exhibiting good sensitivity.
[0048] Example 6: Western Blot Identification of Anti-pNP868R Monoclonal Antibody
[0049] ASFV strain CN / GS / 2018 was used to infect PAMs with an MOI of 1. Cell samples were collected at 0, 12, 24, 36, and 48 h post-infection. After cell treatment, pNP868R protein expressed at different time points after ASFV infection was identified using the anti-pNP868R monoclonal antibody 6C14E11 (A), and pNP868R protein expressed 24 h after ASFV infection was identified using different concentrations of the anti-pNP868R monoclonal antibody 6C14E11 (B). These results were then subjected to Western blotting.
[0050] The results are as follows Figure 5 As shown, when monoclonal antibody 6C1 4E11 was used as the primary antibody, a specific band appeared at 99 kDa, consistent with the expected protein size. Furthermore, the protein expression level increased with prolonged infection time. A clear band was still visible even after incubation with higher dilutions of monoclonal antibody 6C1 4E11. These results indicate that the monoclonal antibody described in this application exhibits strong reactivity and high sensitivity to the pNP868R protein expressed in PAMs infected with ASFV.
[0051] Example 7: Indirect immunofluorescence assay for identification of anti-pNP868R monoclonal antibody
[0052] PAMs were seeded in 24-well plates and cultured for 6 h. ASFV CN / GS / 2018 strain was then infected with PAMs at MOI=1, with uninfected PAMs serving as a control. After 24 h, the cell culture medium was discarded, and 4% tissue fixative was added to the wells to fix the cell morphology. Cells were then permeabilized and blocked using monoclonal antibody 6C1 4E11 (1:2000) as the primary antibody, incubated at room temperature for 2 h, with PBS as a negative control. After incubation, the cells were washed three times with PBST, and then incubated for 1 h in the dark with Alexa Fluor 488-labeled goat anti-mouse (1:5000) as the secondary antibody, followed by washing three times with PBST. 200 μL of DAPI (1:5000) was added to each well, and the cells were incubated in the dark for 10 min, followed by washing three times with PBST. Finally, 400 μL of PBST was added to each well, and the samples were observed under a fluorescence microscope. The reactivity of the virus in PAM cells infected with African swine fever virus was determined.
[0053] The results are as follows Figure 6As shown, when monoclonal antibody 6C1 4E11 was used as the primary antibody, PAMs cells infected with ASFV showed green fluorescence, while PAMs not infected with ASFV did not show fluorescence; however, when PBS was used as the primary antibody, PAMs infected with ASFV also showed no fluorescence. This result indicates that the monoclonal antibody described in this application can specifically recognize the pNP868R protein expressed in ASFV-infected PAMs.
[0054] Example 8 Identification of anti-pNP868R monoclonal antibody subtype Hybridoma cell line 6C1 4E11 was selected for subtype identification using the Proteintech kit instructions: the hybridoma cell supernatant was diluted 1:100 and added to the wells of the strip samples, with 3 replicates; 1× goat anti-mouse IgM+IgG-HRP was added to the kit and incubated at room temperature for 1 h; after incubation, the liquid in the wells was discarded, and the cells were washed 3 times with 1×PBST; 100 μL of chromogenic solution was added to each well, and the cells were incubated at room temperature for 5 min, followed by the addition of stop solution; the absorbance at 450 nm was read using a microplate reader.
[0055] The results are as follows Figure 7 As shown, the monoclonal antibody described in this application belongs to the IgG1 type.
[0056] The variable regions of the heavy chains are VH-FR1, VH-CDR1, VH-FR2, VH-CDR2, VH-FR3, VH-CDR3, and VH-FR4; the variable regions of the light chains are VL-FR1, VL-CDR1, VL-FR2, VL-CDR2, VL-FR3, VL-CDR3, and VL-FR4. Specifically: VH-FR1: EVKLEESGGGLAQPGGSMKLSCVAS (shown as SEQ ID NO.2); VH-CDR1: GFTFSNFW (shown as SEQ ID NO.3); VH-FR2: MNWVRQSPEKGLEWVAE (shown in SEQ ID NO.4); VH-CDR2: IRLKSNNYAT (shown in SEQ ID NO.5); VH-FR3: HYAESVKGRFTISRDDSKSSVYLQMNNLRAEDTGIYYC (shown in SEQ ID NO. 6); VH-CDR3: TNYYRYFDY (shown in SEQ ID NO.7); VH-FR4: WGQGTLVTVSA (shown in SEQ ID NO.8); VL-FR1; QIVLTQSPAIMSASPGEKVTLTCSAS (shown in SEQ ID NO.9); VL-CDR1: SSVSSSY (shown in SEQ ID NO.10); VL-FR2: LYWYQQKPGSSPKLWIY (shown in SEQ ID NO. 11); VL-CDR2: STS (shown as SEQ ID NO.12); VL-FR3: NLASGVPTRFSGSGSGSGTSYSLTISSMEAEDAASYFC (shown in SEQ ID NO. 13); VL-CDR3: HQWSSYPPT (shown in SEQ ID NO.14); VL-FR4: FGGGTKLEIK (shown in SEQ ID NO.15).
[0057] Example 9: Preliminary identification of pNP868R interacting proteins based on anti-pNP868R monoclonal antibody
[0058] To investigate the role of ASFV pNP868R in viral infection and explore the interaction network between pNP868R protein and host viral proteins, PAMs were infected with ASFV CN / GS / 2018 strain. Approximately 48 hours after infection, cells were collected, lysed, and cellular protein samples were obtained. An immunoprecipitation assay was performed using the pNP868R monoclonal antibody 6C1 4E11 and Protein A / G agarose, with mouse IgG used as a negative control. The immunoprecipitated samples were then subjected to Western blot and silver staining detection. The principle of capturing proteins interacting with pNP868R protein is as follows: Immunoprecipitation (CO-IP) was performed using the pNP868R monoclonal antibody, combined with liquid chromatography-mass spectrometry / mass spectrometry (LC-MS / MS) to identify and analyze differentially expressed protein bands.
[0059] The results are as follows Figure 8 As shown, the monoclonal antibody 6C1 4E11 incubated the infected group and showed a clear band at approximately 99 kDa, while the control group did not have this specific band. This indicates that Protein A / G binds to the monoclonal antibody 6C1 4E11, while the pNP868R protein binds to the monoclonal antibody.
[0060] like Figure 9 As shown, the samples after immunoprecipitation were subjected to silver staining again, and the results showed that two differential bands appeared in the lanes of the monoclonal antibody 6C14E11 incubated and infected group.
[0061] The above results indicate that the monoclonal antibody against African swine fever virus pNP868R protein described in this application can be used to capture proteins that interact with pNP868R protein, providing a theoretical basis for further elucidating the pathogenic mechanism of ASFV.
Claims
1. A monoclonal antibody against the pNP868R protein of African swine fever virus, characterized in that, The monoclonal antibody includes a heavy chain variable region and a light chain variable region; the heavy chain variable region includes CDR1 shown in SEQ ID NO.3, CDR2 shown in SEQ ID NO.5, and CDR3 shown in SEQ ID NO.7; the light chain variable region includes CDR1 shown in SEQ ID NO.10, CDR2 shown in SEQ ID NO.12, and CDR3 shown in SEQ ID NO.
14.
2. The monoclonal antibody as described in claim 1, characterized in that, The heavy chain variable region further includes FR1 shown in SEQ ID NO.2, FR2 shown in SEQ ID NO.4, FR3 shown in SEQ ID NO.6, and FR4 shown in SEQ ID NO.8; the light chain variable region further includes FR1 shown in SEQ ID NO.9, FR2 shown in SEQ ID NO.11, FR3 shown in SEQ ID NO.13, and FR4 shown in SEQ ID NO.
15.
3. The monoclonal antibody as described in claim 1, characterized in that, Both the heavy and light chains of the monoclonal antibody are of the IgG1 type.
4. A nucleic acid, characterized in that, The nucleic acid encodes the monoclonal antibody according to any one of claims 1-3.
5. The use of the monoclonal antibody as described in any one of claims 1-3 in the preparation of reagents, test strips, or kits for detecting African swine fever virus.
6. A kit for detecting African swine fever virus, characterized in that, The kit includes the monoclonal antibody as described in any one of claims 1-3.
7. The use of the monoclonal antibody as described in any one of claims 1-3 or the kit as described in claim 6 in the in vitro detection of African swine fever virus for non-disease diagnosis purposes.
8. Use of the monoclonal antibody as described in any one of claims 1-3 in capturing proteins that interact with pNP868R.
9. The method for preparing the monoclonal antibody according to any one of claims 1-3, characterized in that, The method includes: using African swine fever virus pNP868R recombinant protein as an antigen, inoculating BALB / c mice, taking spleen cells from immunized mice and fusing them with SP2 / 0 myeloma cells, obtaining hybridoma cells after subclonal screening and indirect ELISA identification, and the hybridoma cells producing monoclonal antibodies as described in any one of claims 1-3.
10. The preparation method according to claim 9, characterized in that, The amino acid sequence of the recombinant protein of African swine fever virus pNP868R is shown in SEQ ID NO.1.
